BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30675706)

  • 1. Should Multidisciplinary Treatment Differ for Esophageal Adenocarcinoma Versus Esophageal Squamous Cell Cancer?
    Cools-Lartigue J; Ferri L
    Ann Surg Oncol; 2019 Apr; 26(4):1014-1027. PubMed ID: 30675706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
    Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ;
    Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach.
    Suzuki G; Yamazaki H; Aibe N; Masui K; Sasaki N; Shimizu D; Kimoto T; Shiozaki A; Dohi O; Fujiwara H; Ishikawa T; Konishi H; Naito Y; Otsuji E; Yamada K
    Radiat Oncol; 2018 Dec; 13(1):246. PubMed ID: 30547811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy.
    Kumagai K; Mariosa D; Tsai JA; Nilsson M; Ye W; Lundell L; Rouvelas I
    Dis Esophagus; 2016 Oct; 29(7):734-739. PubMed ID: 26316181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
    Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.
    Smithers BM; Thomson I
    Thorac Surg Clin; 2013 Nov; 23(4):509-23. PubMed ID: 24199701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre.
    Saigí M; Oliva M; Aliste L; Calvo M; Hormigo G; Serra Ò; Boladeras A; Farran L; Robles J; Creus G; Paúles MJ; Gornals JB; de Lama E; Borràs JM; Sala N; Galán M
    PLoS One; 2017; 12(9):e0184737. PubMed ID: 28931046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
    McKenzie S; Mailey B; Artinyan A; Metchikian M; Shibata S; Kernstine K; Kim J
    Ann Surg Oncol; 2011 Feb; 18(2):551-8. PubMed ID: 20839062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP
    Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus.
    Salcedo J; Suen SC; Bian SX
    Cancer Med; 2020 Jan; 9(2):440-446. PubMed ID: 31749330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.